...
首页> 外文期刊>European journal of nutrition >Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
【24h】

Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial

机译:菊粉型Fructans对2型糖尿病粪便微生物和短链脂肪酸的益生元效应:随机对照试验

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Compared to a healthy population, the gut microbiota in type 2 diabetes presents with several unfavourable features that may impair glucose regulation. The aim of this study was to evaluate the prebiotic effect of inulin-type fructans on the faecal microbiota and short-chain fatty acids (SCFA) in patients with type 2 diabetes. Methods The study was a placebo controlled crossover study, where 25 patients (15 men) aged 41-71 years consumed 16 g of inulin-type fructans (a mixture of oligofructose and inulin) and 16-g placebo (maltodextrin) for 6 weeks in randomised order. A 4-week washout separated the 6 weeks treatments. The faecal microbiota was analysed by high-throughput 16S rRNA amplicon sequencing and SCFA in faeces were analysed using vacuum distillation followed by gas chromatography. Results Treatment with inulin-type fructans induced moderate changes in the faecal microbiota composition (1.5%, p = 0.045). A bifidogenic effect was most prominent, with highest positive effect on operational taxonomic units (OTUs) of Bifidobacterium adolescentis, followed by OTUs of Bacteroides. Significantly higher faecal concentrations of total SCFA, acetic acid and propionic acid were detected after prebiotic consumption compared to placebo. The prebiotic fibre had no effects on the concentration of butyric acid or on the overall microbial diversity. Conclusion Six weeks supplementation with inulin-type fructans had a significant bifidogenic effect and induced increased concentrations of faecal SCFA, without changing faecal microbial diversity. Our findings suggest a moderate potential of inulin-type fructans to improve gut microbiota composition and to increase microbial fermentation in type 2 diabetes.
机译:目的与健康的人口相比,2型糖尿病肠道微生物群具有几种可能损害葡萄糖调节的不利特征。本研究的目的是评估患有2型糖尿病患者粪便蛋白型FRUCTAN和短链脂肪酸(SCFA)的益生菌作用。方法该研究是一种安慰剂控制的交叉研究,其中25名患者(15名男性)41-71岁,含有16克菊粉型FRUCTANS(寡核苷酸和菊粉的混合物)和16-G安慰剂(麦芽糖糊精)6周随机顺序。 4周的洗涤液分开了6周的治疗方法。通过高通量16S分析粪便微生物,通过高通量16S分析RRNA扩增子测序,使用真空蒸馏分析粪便中的SCFA,然后进行气相色谱。结果治疗菊粉型FRUCTAN诱导粪便微生物群组合物中等变化(1.5%,P = 0.045)。双歧酰胺效果最突出,具有最高的双歧杆菌肌杆菌的分类单位(Otus)的最高积极作用,其次是菌斑的Otus。与安慰剂相比,在益生菌消费后,检测到总SCFA的粪便浓度显着更高。益生元纤维对丁酸或整体微生物多样性的浓度没有影响。结论含有菊粉型Fructans的补充六周具有显着的双歧杆菌作用,诱导粪便SCFA的浓度增加,而不会改变粪便微生物多样性。我们的研究结果表明,菊粉型Fructans的适度潜力,以改善肠道微生物群组成,并增加2型糖尿病中的微生物发酵。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号